Evaluation of Clinical outcomes of third-line therapies in aGvHD patients with gastrointestinal involvement, Refractory to corticosteroids and ruxolitinib: a Non-interventional retrospective Study.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
MAAT PHARMA
Cita
Evaluation of Clinical outcomes of third-line therapies in aGvHD patients with gastrointestinal involvement, Refractory to corticosteroids and ruxolitinib: a Non-interventional retrospective Study. (MPOH09). MAAT PHARMA. 2025IP:JAIME SANZ CABALLER.
Portal de investigación